Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 45.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,780 shares of the company’s stock after selling 14,809 shares during the period. Victory Capital Management Inc.’s holdings in Harmony Biosciences were worth $574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. ELCO Management Co. LLC acquired a new stake in shares of Harmony Biosciences during the third quarter worth $210,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Harmony Biosciences during the fourth quarter valued at $210,000. Raymond James & Associates purchased a new stake in Harmony Biosciences in the third quarter valued at $216,000. China Universal Asset Management Co. Ltd. boosted its holdings in Harmony Biosciences by 342.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,777 shares of the company’s stock valued at $219,000 after purchasing an additional 5,244 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Harmony Biosciences by 64.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,796 shares of the company’s stock valued at $255,000 after purchasing an additional 3,060 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 11,979 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Down 2.8 %

Shares of Harmony Biosciences stock opened at $29.35 on Friday. The firm has a 50-day simple moving average of $30.85 and a two-hundred day simple moving average of $30.92. The company has a market cap of $1.67 billion, a P/E ratio of 12.71, a price-to-earnings-growth ratio of 0.52 and a beta of 0.75. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $39.26. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.07 and a current ratio of 3.11.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a net margin of 22.30% and a return on equity of 28.26%. The firm had revenue of $154.62 million during the quarter, compared to the consensus estimate of $154.10 million. During the same quarter in the prior year, the firm earned $0.48 EPS. The company’s revenue for the quarter was up 29.8% on a year-over-year basis. As a group, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HRMY has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Harmony Biosciences in a report on Friday, April 12th. Mizuho lowered their price target on shares of Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 30th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, Harmony Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $40.63.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.